Ypsomed and Medical Technology and Devices (MTD) have completed the sale of the pen needle and blood glucose monitoring (BGM) systems business. Switzerland-based Ypsomed develops and manufactures injection and infusion systems for self-medication and a renowned diabetes specialist. MTD is a consumer health group owning a portfolio of global brands with a leading position across diabetes, medical sharps, wound care, heart monitors, thermometers & nebulizers.
The transaction marks a pivotal moment for both companies. For Ypsomed, it enables the company to focus its diabetes care business on commercialisation and development of its mylife Loop insulin pump solution. For MTD, it marks a major step forward in its mission to provide superior diabetes and obesity care solutions on a global scale.
With the acquisition, MTD strengthens its position as the clear number two in the global pen needles market. It solidifies its position in diabetes care and underscores its commitment to delivering solutions for both self-care and professional use. The firm will integrate Ypsomed’s pen needles operations into its European production and distribution network, bringing total production capacity to over 2.5 billion pen needles.
The acquisition provides entry into strategic, high-growth markets such as China and India, and enhances MTD’s presence in established markets, including North America, Germany and France.
In line with its growth strategy, MTD is implementing a substantial investment plan to establish the most competitive production facilities for pen needles and lancets in Europe. The investments aim to increase capacity and enhance the performance, quality, and ESG credentials of its production operations.
During a transition period, Ypsomed will produce pen needles as a contract manufacturer. The production equipment will be gradually moved to the MTD sites by mid-2025. The vacant space will be used for new tool making facilities at Ypsomed’s Solothurn site.
MTD was supported by Studio Legale LCA for the legal aspects, with Roberto de Bonis, Sara Consoli and Mario Niggeler.